^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 negative

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related tests:
1d
HER2-dependent paraptosis and ferroptosis induction by cannabidiol in breast cancer cells. (PubMed, Biochim Biophys Acta Mol Basis Dis)
These findings support a model in which CBD downregulates HER2 and, in a HER2-dependent context, promotes paraptosis and ferroptosis. In addition, docking and molecular dynamics analyses suggested a potential interaction between CBD and HER2, providing mechanistic insights into possible molecular recognition relevant to HER2-positive breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
|
HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 positive + HER-2 overexpression
1d
Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer. (PubMed, Discov Oncol)
Clinicopathological characteristics and baseline peripheral lymphocyte subsets were significantly associated with efficacy of first-line chemotherapy combined with ICIs in pMMR HER2-negative advanced G/GEJC, highlighting the potential utility of integrating these accessible parameters for efficacy prediction.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 negative
1d
Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
P=N/A, N=6097, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Ibrance (palbociclib) • letrozole
1d
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
|
HER-2 negative • ER negative
|
methoxsalen (X-PACT)
1d
FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
P2, N=80, Not yet recruiting, Sun Yat-sen University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
|
docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
2d
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2. (PubMed, Breast)
Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.
Journal • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
2d
Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer. (PubMed, Cancer Treat Res Commun)
Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
3d
Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study. (PubMed, Int J Clin Oncol)
An ALC ≥ 1000/μL at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Halaven (eribulin mesylate)
3d
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
3d
Treatment pattern and preferences of locally advanced and metastatic HR+, HER2- breast cancer from a Chinese physician and patient survey (ChiCTR2600116892)
P=N/A, N=320, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive
3d
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab)
3d
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative